Mansoori et al. reported that miR-142 can target Bach-1 in breast cancer cells, thereby down-regulating the expression of C–X–C chemokine receptor type 4 (CXCR4), matrix metalloproteinase 9 (MMP9) and vascular endothelial growth factor receptor (VEGFR) [32]. Here, BACH1 is linked to breast carcinoma.